Transforming 
drug discovery with generative AI

Evolving at the intersection of AI and drug discovery

Our team brings together deep expertise across machine learning, medicinal chemistry, and computational chemistry, applied to the challenges of small molecule drug discovery. Our AI scientists have been trained and conducted research at some of the world’s leading academic and industrial laboratories, including MIT, Caltech, Berkeley, Google, Microsoft Research, and D-Wave Quantum, and combine cutting-edge expertise in generative modeling with strong foundations in applied mathematics and computational science. Alongside experienced medicinal and computational chemists with first-hand pharmaceutical R&D experience, Variational AI’s multidisciplinary team ensures that Enki is grounded in rigorous science and built as a practical solution to real-world discovery programs.

Our Team

Handol Kim

Jason Rolfe, PhD

Ali Saberali, PhD

Peter Guzzo, PhD

Roslynn Drewitt-Lange

Ahmad Issa, PhD

Marshall Drew-Brook

Sara Ibrahim Omar, PhD

Alex Perryman, PhD

Brian Atwood, PhD

Matthew Quenneville, PhD

James McSally, PhD

Yizhou Zhang, PhD

Jérôme Rony, PhD

Valentin Beuchillot

Sumin Park

Mahdi Gilany, PhD

Boards of Directors

Frank Chang

Handol Kim

Hanqing Li

Jason Robertson

Jason Rolfe, PhD

Scientific Advisory Board

John Boylan, PhD

Artem Cherkasov, PhD

Alexander Tropsha, PhD

Robert N. Young, PhD

Advisors

Jennifer Hamilton, PhD

Nancy Harrison

Todd Farrell

Paul Davie

Variational AI is backed by top-tier investors in healthcare, life sciences, and artificial intelligence.

Our investors include: Nimbus Synergies, Merck Global Health Innovation Fund, Flying Fish Ventures, A&E Investments, Nepenthe Capital, and an alliance of Angel investors. This support fuels the continued development of our generative AI platform, Enki, and strengthens our ability to collaborate with biopharma partners across therapeutic areas.

Looking to contact us? Reach out for more information